Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study

Adomas Bunevicius, Stylianos Pikis, Douglas Kondziolka, Dev N. Patel, Kenneth Bernstein, Erik P. Sulman, Cheng chia Lee, Huai che Yang, Violaine Delabar, David Mathieu, Christopher P. Cifarelli, David E. Arsanious, Basem A. Dahshan, Joshua S. Weir, Herwin Speckter, Angel Mota, Manjul Tripathi, Narendra Kumar, Ronald E. Warnick, Selcuk PekerYavuz Samanci, Gene Barnett, Farid El Hefnawi, Ghusn Al Sideiri, Jason Sheehan*


研究成果: Article同行評審

1 引文 斯高帕斯(Scopus)


Objective: Isocitrate dehydrogenase (IDH) mutation status is recommended used for diagnosis and prognostication of glioblastoma patients. We studied efficacy and safety of stereotactic radiosurgery (SRS) for patients with recurrent IDH-wt glioblastoma. Methods: Consecutive patients treated with SRS for IDH-wt glioblastoma were pooled for this retrospective observational international multi-institutional study from institutions participating in the International Radiosurgery Research Foundation. Results: Sixty patients (median age 61 years) underwent SRS (median dose 15 Gy and median treatment volume: 7.01 cm3) for IDH-wt glioblastoma. All patients had histories of surgery and chemotherapy with temozolomide, and 98% underwent fractionated radiation therapy. MGMT status was available for 42 patients, of which half of patients had MGMT mutant glioblastomas. During median post-SRS imaging follow-up of 6 months, 52% of patients experienced tumor progression. Median post-SRS progression free survival was 4 months. SRS prescription dose of > 14 Gy predicted longer progression free survival [HR 0.357 95% (0.164–0.777) p = 0.009]. Fifty-percent of patients died during post-SRS clinical follow-up that ranged from 1 to 33 months. SRS treatment volume of > 5 cc emerged as an independent predictor of shorter post-SRS overall survival [HR 2.802 95% CI (1.219–6.444) p = 0.02]. Adverse radiation events (ARE) suggestive of radiation necrosis were diagnosed in 6/55 (10%) patients and were managed conservatively in the majority of patients. Conclusions: SRS prescription dose of > 14 Gy is associated with longer progression free survival while tumor volume of > 5 cc is associated with shorter overall survival after SRS for IDH-wt glioblastomas. AREs are rare and are typically managed conservatively.

頁(從 - 到)343-351
期刊Journal of Neuro-Oncology
出版狀態Published - 12月 2021


深入研究「Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study」主題。共同形成了獨特的指紋。